ICON Health & Fitness Announces $200 Million Growth Investment Led By L Catterton

Investment Will Further Accelerate Growth of Fitness Leader’s Connected Equipment and Industry-leading Subscription Technology Platform iFit

ICON Health & Fitness (“ICON”), the world leader in innovation, design and distribution of connected fitness equipment and software, today announced a $200 million growth investment led by L Catterton, the largest and most global consumer-focused private equity firm, and is joined by existing investor Pamplona Capital Management.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201005005720/en/

(Photo: Business Wire)

ICON owns established industry-leading fitness brands NordicTrack®, ProForm® and Freemotion®, which offer connected fitness membership services powered by iFit, the immersive live and on-demand streaming fitness and wellness media platform.

With revenue exceeding $1 billion in the last 12 months (ending September 30, 2020), ICON is the only company which creates connected fitness experiences across multiple brands, multiple product categories and all consumer fitness segments.

The investment will further accelerate ICON’s unique

Read More

6-year-old boy’s death led to investigation that found brain-eating amoeba in Texas city’s water supply

An investigation into a 6-year-old boy’s death led to the detection of a brain-eating amoeba in a Houston-area city’s water supply, health officials confirmed this weekend. CBS affiliate KHOU-TV reported Josiah McIntyre was hospitalized earlier this month after contracting naegleria fowleri at either the Lake Jackson splashpad or a hose at his family’s home.

The investigation into his Sept. 8 death led to the detection of the brain-eating amoeba after heath officials conducted water sample tests, Lake Jackson City Manager Modesto Mundo said in a news release Saturday.

Three of 11 sample tests indicated preliminary positive

Read More

InventisBio Announces $147 Million Series D Financing Led by Hillhouse Affiliate GL Ventures

SHANGHAI, Sept. 28, 2020 /PRNewswire/ — InventisBio, a clinical stage biotech company dedicated to the research and development of innovative small molecule drugs, announced the recent completion of a $147 million series D financing which has attracted participation of many top biopharmaceutical and healthcare venture capital funds. This round of investment was led by Hillhouse affiliate GL Ventures, followed by Qiming Venture Partners, Janchor, AIHC Capital, Matrix Partner China, Dyee Capital, E Fund Capital and other investors. The existing shareholders including Lilly Asia Venture, OrbiMed Asia, Pudong Innotek, AdvanTech Capital, and CMB International continued their support. China Renaissance was the exclusive financial advisor of this transaction.

Logo
Logo

Currently InventisBio has three drug products in the mid- to late-stage clinical development, and one new product just entered global phase I clinical study. Among them, D-0502 is an oral selective estrogen receptor degrader (SERD), which also acts as an estrogen

Read More